Getagraph.com logo
S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.47%) $78.85
Gas
(0.46%) $2.21
Gold
(0.13%) $2 334.20
Silver
(0.24%) $27.68
Platinum
(0.17%) $966.50
USD/EUR
(-0.05%) $0.928
USD/NOK
(-0.46%) $10.82
USD/GBP
(-0.13%) $0.796
USD/RUB
(-0.13%) $91.34

Realtime updates for Altimmune Inc [ALT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-09)

Expected move: +/- 13.90%

BUY
47.50%
return 2.42%
SELL
37.50%
return 6.91%
Last Updated6 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

0.82% $ 7.36

SELL 44775 min ago

@ $9.09

Issued: 5 Apr 2024 @ 16:00

Return: -19.03%

Previous signal: Apr 4 - 14:18

Previous signal: Buy

Return: -0.66 %

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:00):

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis...

Stats
Today's Volume 1.39M
Average Volume 4.68M
Market Cap 521.79M
EPS $0 ( 2024-03-27 )
Next earnings date ( $-0.360 ) 2024-05-09
Last Dividend $873.01 ( 2017-01-20 )
Next Dividend $0 ( N/A )
P/E -4.43
ATR14 $0.0110 (0.15%)
Insider Trading
Date Person Action Amount type
2024-02-02 Roberts M Scot Buy 7 775 Common Stock, par value $0.0001
2024-02-02 Roberts M Scot Sell 2 330 Common Stock, par value $0.0001
2024-02-01 Roberts M Scot Buy 6 166 Common Stock, par value $0.0001
2024-02-01 Roberts M Scot Sell 1 801 Common Stock, par value $0.0001
2024-02-02 Roberts M Scot Sell 7 775 Restricted Stock Units
INSIDER POWER
81.81
Last 99 transactions
Buy: 2 849 671 | Sell: 279 919

Volume Correlation

Long: 0.05 (neutral)
Short: 0.91 (very strong)
Signal:(71.135) Expect same movement, but be aware

Altimmune Inc Correlation

10 Most Positive Correlations
EBET0.973
APEI0.968
STRM0.966
SY0.964
ENTA0.963
IMBI0.963
CASA0.958
SISI0.958
CAMP0.957
NSTG0.957
10 Most Negative Correlations
LDHA-0.979
JUGG-0.979
ADAL-0.978
CRZN-0.977
HORI-0.976
AHRN-0.974
AGGR-0.974
TBSA-0.974
HCNE-0.973
LEGA-0.973

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Altimmune Inc Correlation - Currency/Commodity

The country flag -0.73
( moderate negative )
The country flag -0.51
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.29
( neutral )
The country flag 0.15
( neutral )
The country flag 0.75
( moderate )

Altimmune Inc Financials

Annual 2023
Revenue: $426 000
Gross Profit: $-51 000.00 (-11.97 %)
EPS: $-1.660
FY 2023
Revenue: $426 000
Gross Profit: $-51 000.00 (-11.97 %)
EPS: $-1.660
FY 2022
Revenue: $-68 000.00
Gross Profit: $-136 000 (200.00 %)
EPS: $-1.810
FY 2021
Revenue: $4 410.00
Gross Profit: $0.00 (0.00 %)
EPS: $-0.00379

Financial Reports:

No articles found.

Altimmune Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Altimmune Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $873.01 2017-01-20
Last Dividend $873.01 2017-01-20
Next Dividend $0 N/A
Payout Date 2017-02-03
Next Payout Date N/A
# dividends 1 --
Total Paid Out $873.01 --
Avg. Dividend % Per Year 0.00% --
Score 0.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-05-06)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
0.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2017 $873.01 655.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Royal 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-203.671.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.4121.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.5101.500-6.78-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM17.250.80010.008.00[1 - 3]
quickRatioTTM16.690.80010.008.00[0.8 - 2.5]
cashRatioTTM11.131.50010.0010.00[0.2 - 2]
debtRatioTTM0.00319-1.5009.95-10.00[0 - 0.6]
interestCoverageTTM3 630.871.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-1.2972.00-0.432-0.865[0 - 30]
freeCashFlowPerShareTTM-1.2982.00-0.649-1.298[0 - 20]
debtEquityRatioTTM0.00346-1.5009.99-10.00[0 - 2.5]
grossProfitMarginTTM-76.881.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-196.031.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-112.981.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.002020.800-3.32-2.66[0.5 - 2]
Total Score-0.982

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-4.921.000-0.5980[1 - 100]
returnOnEquityTTM-0.5102.50-4.36-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.2982.00-0.433-1.298[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-1.2972.00-0.432-0.865[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.07131.500-3.810[0.5 - 2]
operatingCashFlowSalesRatioTTM-177.961.000-10.000[0.1 - 0.5]
Total Score-2.80

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators